Mergers and Acquisitions Takeover Bids

  • Michael Pearson, CEO of Valeant Pharmaceuticals.

    Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.

  • If Time Warner-FOX deal happens

    CNBC's Julia Boorstin provides insight to the reaction in shares of cable companies after a $80 billion takeover offer from 21st Century Fox for Time Warner was rejected.

  • Close look at Time Warner's rejection

    CNBC's Andrew Ross Sorkin provides insight to the $80 billion takeover offer from 21st Century Fox for Time Warner, which was rejected.

  • Allergan fighting Ackman

    CNBC's David Faber discusses Bill Ackman's backing of Valeant's takeover bid for Allergan. Allergan CEO David Pyott has bone to pick with Ackman.

  • Faber Report: AbbVie sticks with $46 billion offer for Shire

    CNBC's David Faber provides insight to AbbVie's $46 billion case to take over Shire.

  • Cramer: AbbVie-Shire driven by inversion

    British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.

  • Valeant goes hostile in bid for Allergan

    Valeant says it will launch an exchange offer to Allergan shareholders, reports CNBC's Meg Tirrell.

  • Medtronic CEO: Focused on organic growth

    Omar Ishrak, Medtronic chairman & CEO, discusses the state of the health care industry and explains the extensive M&A activity happening in the sector.

  • Unusual options around Hillshire Brands

    FMHR trader Pete Najarian takes a close look at unusual activity in options for Hillshire Brands, and the action in its stock as takeover talks continue.

  • Fight for Hillshire

    Pilgrim's Pride is sweetening its takeover offer for Hillshire Brands. CNBC's Jim Cramer and David Faber discuss the "insane" bidding for Hillshire.

  • Gabelli's stocks to watch: Kinnevik & Natural Fuel Gas

    Mario Gabelli, Gamco Investors chairman & CEO, shares his thoughts on how to play the social media, e-commerce, and natural gas space.

  • Gabelli eyes takeover targets

    Mario Gabelli, Gamco Investors chairman & CEO, explains why he is watching shares of Protective Life, Interpublic Group, and Hillshire Brands.

  • Cramer: Many reasons to own Tyson

    Tyson Foods is jumping in the takeover battle for Hillshire. The "Squawk on the Street" news team discuss Tyson's $50 a share offer.

  • 2014: Best M&A year ever?

    This year has been the year of mergers, acquisitions and hostile takeovers. Attorney Frank Aquila, Sullivan & Cromwell, discusses what's behind the recent M&A boom.

  • Cramer: Hillshire needs to buy Birds Eye

    The "Squawk on the Street" take a close look at the offer from Pilgrim's Pride for Hillshire Brands. Pilgrim's Pride wants Hillshire to drop Pinnacle Foods of which Birds Eye Foods is a brand.

  • Cramer: Allergan needs Valeant deal

    CNBC's David Faber and Jim Cramer discuss the latest M&A action, including Valeant Pharmaceuticals raising its takeover bid for Allergan, and GE improving its offer for France's Alstom.

  • Hillshire responds to Pilgrim's Pride takeover offer

    CNBC's Dominic Chu reports Hillshire Brands has responded to the proposal by Pilgrim's Pride to acquire Hillshire for about $6.4 billion

  • Hillshire gets takeover offer from Pilgrim's Pride

    The "Squawk on the Street" news team discusses the report that Pilgrim's Pride is offering to acquire Hillshire Brands for $6.4 billion.

  • Cramer eyes food fight

    Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today Cramer shares his thoughts on Pilgrim Pride's bid for Hillshire Brands.

  • Pfizer drops bid for AstraZeneca

    John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.